Evidence map›Paper›PMID 26901461›Full record

ArticleBiosensors & bioelectronics2016

Using DNA devices to track anticancer drug activity.

Dimithree Kahanda, Gaurab Chakrabarti, Marc A Mcwilliams, David A Boothman, Jason D Slinker

Open access · greenAbstract read
In one paragraph

Article in Biosensors & bioelectronics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dimithree KahandaDepartment of Physics, The University of Texas at Dallas, 800 W. Campbell Rd., PHY 36, Richardson, TX 75080, United States.
Gaurab ChakrabartiDepartments of Pharmacology, Oncology and Radiation Oncology, Laboratory of Molecular Stress Responses and the Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, ND2.210K 601 Forest Park Drive, Dallas, TX 75390-8807, United States.
Marc A McwilliamsDepartment of Physics, The University of Texas at Dallas, 800 W. Campbell Rd., PHY 36, Richardson, TX 75080, United States.
David A BoothmanDepartments of Pharmacology, Oncology and Radiation Oncology, Laboratory of Molecular Stress Responses and the Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, ND2.210K 601 Forest Park Drive, Dallas, TX 75390-8807, United States.
Jason D SlinkerDepartment of Physics, The University of Texas at Dallas, 800 W. Campbell Rd., PHY 36, Richardson, TX 75080, United States. Electronic address: slinker@utdallas.edu.
The University of Texas at Dallas · USThe University of Texas Southwestern Medical Center · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
Use of Beta-Lapachone for Lung Cancer ChemotherapyR01CA102792 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BOOTHMAN, DAVID A · 2003 to 2017
$5.3M
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivityR01CA210489 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MOTEA, EDWARD AYSON · 2016 to 2020
$1.8M
NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA102792NCI NIH HHS R01 CA210489PHS HHS R01102792
6 · The paper itself

Abstract

It is beneficial to develop systems that reproduce complex reactions of biological systems while maintaining control over specific factors involved in such processes. We demonstrated a DNA device for following the repair of DNA damage produced by a redox-cycling anticancer drug, beta-lapachone (β-lap). These chips supported ß-lap-induced biological redox cycle and tracked subsequent DNA damage repair activity with redox-modified DNA monolayers on gold. We observed drug-specific changes in square wave voltammetry from these chips at therapeutic ß-lap concentrations of high statistical significance over drug-free control. We also demonstrated a high correlation of this change with the specific ß-lap-induced redox cycle using rational controls. The concentration dependence of ß-lap revealed significant signal changes at levels of high clinical significance as well as sensitivity to sub-lethal levels of ß-lap. Catalase, an enzyme decomposing peroxide, was found to suppress DNA damage at a NQO1/catalase ratio found in healthy cells, but was clearly overcome at a higher NQO1/catalase ratio consistent with cancer cells. We found that it was necessary to reproduce key features of the cellular environment to observe this activity. Thus, this chip-based platform enabled tracking of ß-lap-induced DNA damage repair when biological criteria were met, providing a unique synthetic platform for uncovering activity normally confined to inside cells.

Indexed as

Biosensing TechniquesDNA RepairAntineoplastic AgentsCatalaseCell Line, TumorDNA DamageGoldHumansNAD(P)H Dehydrogenase (Quinone)NaphthoquinonesAntineoplastic Agentsbeta-lapachoneCatalaseGoldNAD(P)H Dehydrogenase (Quinone)NaphthoquinonesNQO1 protein, humanBase-excision repairBiosensorDNA repairElectrochemical sensorOxidative damage

Identifiers

PMID26901461
PMCPMC4793915
OpenAlexW2271589439

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.